Cosmecca Korea코스메카코리아
241710 · KOSDAQ · ₩241710 · 코스메카코리아
Analyst target price
Average target
₩146,667
Upside
+43.5%
Range ₩140,000 – ₩150,000 · 3 brokers (latest target within 6 months)
Buy 2
Consensus target vs price, 2 years
Earnings estimates
Brokers' earnings estimates and how they've been revised, with Pro.
Unlock with ProBroker reports
| Date | Broker | Report | Rating | Target | Change | Upside | Since publish | Read |
|---|---|---|---|---|---|---|---|---|
| Oct 6 | Kyobo Securities | Steady Progress as Planned | Buy | ₩150,000 | Maintained | +46.8% | −7.4% | Read ↗ |
| Oct 6 | Kyobo Securities | Steady Progress as Planned | Buy | ₩150,000 | New | +46.8% | −7.4% | Read ↗ |
| Sep 28 | Yuanta Securities Korea | 3Q estimates revised down, growth outlook still valid | Buy | ₩150,000 | New | +46.8% | −18.8% | Read ↗ |
Calculated by JONBUR from publicly available broker reports. Reports belong to their publishers. Not financial advice. Includes brokers that publish research publicly; some brokers' reports are client-only and not included.
Reported in the news
| Date | Broker | Target | Change | Rating | Source |
|---|---|---|---|---|---|
| Oct 18 | Sangsangin Investment & Securities | ₩140,000 | — | Reported by Edaily | |
| Oct 12 | KB Securities | — | Raised | — | Reported by The Korea Economic Daily |
Target prices and ratings as news headlines report them, for every broker, including the ones whose reports we don't collect. Only what the headline says; open the article for the rest. Not financial advice.
AI summary of public information
An AI summary of the public information on this company: filed financial statements, filings, prices and news headlines. It doesn't use broker reports; their targets and estimates are shown above.
Cosmecca Korea's profits have grown strongly over recent years, but its share price has fallen 19.7% over the past month.
Cosmecca Korea is a cosmetics contract manufacturer (ODM/OEM) with trailing twelve-month revenue of ₩772B and operating income of ₩102B to H1 2026. Revenue grew 22.2% in 2025, and the company has sites in Korea, China and the United States. The share price was ₩102,200 on 2026-10-26, well below its 52-week high of ₩155,500 but up 50.5% over one year.
What stands out
- Operating margin rose from 2.6% in 2022 to 13.2% on a trailing basis, and net income reached ₩63.8B over the same period.
- Borrowings of ₩226B are about 2.9 times cash of ₩77B, and liabilities are 119.6% of equity.
- The discounted cash flow model gives a base value of ₩100,517, close to the current price, with a bear case of ₩45,959 and a bull case of ₩196,679.
- Foreign ownership rose from 22.1% to 24.5% over the past 60 days, while institutions were net sellers over the last 20 days.
- Filings include a merger decision (September 2026, later amended) and a shareholders' meeting called in October 2026.
What to watch
- The merger decision and its amendments, along with the shareholders' meeting and record-date notices, which the data does not explain in detail.
- Q3 results: news reports say operating profit is expected to rise about 12%, but the official figures are not yet in the data.
- Parts supply disruption, which one broker says should be resolved in Q4; the data does not confirm whether this has happened.
Data as of Oct 26, 2026 · written 23h ago
This is not financial advice.
Also known as: Cosmecca Korea / 코스메카코리아 / 241710 / KRX:241710
Source: KRX statistical information